Published in AIDS Weekly, February 14th, 2000
The majority of patients in both groups also cleared measurable virus from their systems.
The data comparing Cytovene-IV (ganciclovir) and its investigational oral pro-drug, valganciclovir, were presented at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco, California, January 30 - February 2, 2000.
In this study, 160 patients were randomized to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.